Biogen Inc.
Location
Massachusetts
Founded
1978-02-28
Website
Risk Signals
6605 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations, Biological Products, Except Diagnostic Substances, Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Biogen Inc.
Live alerts from global media, monitored by Business Radar
2025-01-12 (defenseworld.net)
Wells Fargo & Company Issues Pessimistic Forecast for Biogen (NASDAQ:BIIB) Stock Price -
Read Wells Fargo & Company Issues Pessimistic Forecast for Biogen (NASDAQ:BIIB) Stock Price at Defense World
Read more
2025-01-08 (marketbeat.com)
Biogen (NASDAQ:BIIB) Price Target Cut to $220.00 by Analysts at Truist Financial
Truist Financial lowered their price target on Biogen from $302.00 to $220.00 and set a "buy" rating on the stock in a report on Wednesday.
Read more
2024-12-20 (marketbeat.com)
Biogen (NASDAQ:BIIB) Cut to Market Perform at BMO Capital Markets
BMO Capital Markets cut shares of Biogen from an "outperform" rating to a "market perform" rating and lowered their price target for the company from $230.00 to $164.00 in a report on Friday.
Read more
2024-12-15 (defenseworld.net)
Biogen (NASDAQ:BIIB) Reaches New 12-Month Low – Here’s Why -
Read Biogen (NASDAQ:BIIB) Reaches New 12-Month Low – Here’s Why at Defense World
Read more
2024-12-09 (marketbeat.com)
Biogen (NASDAQ:BIIB) Rating Lowered to "Hold" at Jefferies Financial Group
Jefferies Financial Group lowered Biogen from a "buy" rating to a "hold" rating and lowered their price objective for the company from $250.00 to $180.00 in a report on Monday.
Read more
2024-11-19 (tipranks.com)
Needham downgrades Biogen to Hold on lack of share catalysts
Needham downgraded Biogen (BIIB) to Hold from Buy without a price target The firm does not see a meaningful source of upside for the shares over the next 12 months....
Read more
2024-10-13 (marketbeat.com)
Short Interest in Biogen Inc. (NASDAQ:BIIB) Decreases By 22.3%
Biogen Inc. (NASDAQ:BIIB - Get Free Report) was the recipient of a large decline in short interest during the month of September. As of September 30th, there was short interest totalling 2,850,000 shares, a decline of 22.3% from the September 15th total of 3,670,000 shares.
Read more
2024-10-05 (defenseworld.net)
Biogen (NASDAQ:BIIB) Price Target Cut to $269.00 by Analysts at Royal Bank of Canada
Biogen (NASDAQ:BIIB – Free Report) had its price target reduced by Royal Bank of Canada from $292.00 to $269.00 in a research report released on Friday, Benzinga reports. Royal Bank of Canada currently has an outperform rating on the biotechnology company’s stock.
Read more
2024-09-12 (reporter.am)
Biogen’s (BIIB) Overweight Rating Reiterated at Cantor Fitzgerald
Read Biogen’s (BIIB) Overweight Rating Reiterated at Cantor Fitzgerald at The AM Reporter
Read more
2024-09-11 (finmarket.ru)
Finam raised its target price for Biogen shares to $241.7
Finam raised its target price for Biogen Inc. shares. to $241.7 per share, which implies a growth potential of 20.4% over a 12-month horizon, according to a commentary by the leading analyst of the investment company Zarina Saidova.
Read more
2024-03-29 (defenseworld.net)
140 Shares in Biogen Inc. (NASDAQ:BIIB) Purchased by CVA Family Office LLC
CVA Family Office LLC acquired a new stake in Biogen Inc. (NASDAQ:BIIB – Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission.
Read more
2023-11-14 (finmarket.ru)
Investbank
Investment bank ``Sinara'' maintains ``hold'' rating for Tesla shares with outlook
Read more